Alfacell stock commences trading on The Nasdaq Stock Market.BLOOMFIELD, N.J.--(BUSINESS WIRE)--Dec. 5, 1996--Alfacell Corp. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :ACEL ACEL Australian Council for Educational Leaders (Australia) ACEL Aerospace Crew Equipment Laboratory ACEL Alternating Current Electro-Luminescent ) announced today that its common stock has commenced trading on the NASDAQ SmallCap Market Securities system beginning today under the symbol "ACEL." The NASDAQ Stock Market Nasdaq stock market The first electronic stock market listing over 5000 companies. The Nasdaq stock market comprises two separate markets, namely the Nasdaq National Market, which trades large, active securities and the Nasdaq Smallcap Market that trades emerging growth companies. is a major national and international stock market that uses computers and telecommunications networks for the trading and surveillance of thousands of securities. Alfacell, a leader in the area of ribonuclease Ribonuclease A group of enzymes, widely distributed in nature, which catalyze hydrolysis of the internucleotide phosphodiester bonds in ribonucleic acid (RNA). (RNase) research, is currently testing its flagship anticancer drug ONCONASE(R) in various clinical trials. Developed by Alfacell scientists, ONCONASE is a novel RNase protein used in the investigational treatment of patients with solid tumors, most of which are resistant to other chemotherapeutic drugs. ONCONASE, the only cytotoxic RNase currently in clinical trials, has been used in the treatment of patients with a variety of solid tumors and has demonstrated in vitro and in vivo activity in multiple-drug resistant (MDR MDR, n See multidrug resistance. MDR, n the abbreviation for minimum daily requirement, specifically the Minimum Daily Requirements for Specific Nutrients compiled by the United States Food and Drug Administration. ) tumor models. MDR is thought to be responsible for approximately 90% of chemotherapy failures. The company is currently conducting multi-center Phase III clinical trials in advanced pancreatic cancer patients, a multi-center Phase II trial in patients with malignant mesothelioma and pilot studies in renal cell carcinoma renal cell carcinoma or hypernephroma Malignant tumour of the cells that cover and line the kidney. It usually affects persons over age 50 who have vascular disorders of the kidneys. It seldom causes pain, unless it is advanced. and prostate cancer. Alfacell, a biopharmaceutical company located in Bloomfield, N.J., is engaged primarily in the research and development of novel ribonuclease enzymes for various therapeutic applications. CONTACT: Alfacell Corp. Donna Brasko, 201/748-8082 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion